Pacira Pharm Inc (PCRX) 44.07 $PCRX Technical Analysis

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 11:15 AM

Pacira Pharm Inc (PCRX) 44.07 $PCRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 12.87 (-0.13), CPRX: 0.62 (-0.03), AKRX: 30.25 (-0.55), PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained
Sean Williams, The Motley Fool - Motley Fool - Mon May 02, 3:02PM CDT
Image source: NIH Image Gallery via Flickr. What: Shares of Pacira Pharmaceuticals , a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10%...
PCRX: 44.07 (-1.34)

Pacira reports 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Monday reported a first-quarter loss of $3.9 million, after reporting a profit in the same period a year earlier.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
-- Total Net Revenues Up 12 Percent Year-Over-Year --
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals Appoints Charles A. Reinhart, III, as Chief Financial Officer
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Charles A. Reinhart, III, to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently President, and will report to Dave Stack, Chief Executive Officer and Chairman. Mr. Reinhart will start in this new role effective Tuesday, May 3, 2016.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals (PCRX) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 7:48AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) has moved higher as of late, but there could definitely be trouble on the horizon for this company
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
GlobeNewswire - Thu Apr 14, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that financial results for the company's first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 54803652.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial Officer.
PCRX: 44.07 (-1.34)

Pacira (PCRX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 9:05AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PCRX: 44.07 (-1.34)

PixarBio's NeuroRelease(TM) A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan as Global VP of Sales & Marketing
BusinessWire - Wed Mar 09, 5:00AM CST
PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.
PCRX: 44.07 (-1.34)

Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 6:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company.
PCRX: 44.07 (-1.34)

CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 84.45 (-1.32), MYL: 44.53 (-1.23), CTIC: 0.43 (-0.01), PCRX: 44.07 (-1.34)

Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MG
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:25PM CST
Catalyst Pharmaceuticals, Inc. (CPRX) announced the initiation of a well-controlled study evaluating the efficacy, safety and tolerability of Firdapse for the treatment of MuSK-MG.
EARS: 3.27 (-0.13), CPRX: 0.62 (-0.03), CORT: 5.60 (+0.13), PCRX: 44.07 (-1.34)

Shire's NDA Resubmission for Lifitegrast Accepted by FDA
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 3:15PM CST
Shire plc (SHPG) announced that the FDA has acknowledged the receipt of the company's New Drug Application (NDA) for its pipeline candidate, lifitegrast.
AGN: 240.93 (-6.47), SHPG: 177.10 (-6.85), CORT: 5.60 (+0.13), PCRX: 44.07 (-1.34)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.02 (-0.11), CORT: 5.60 (+0.13), PCRX: 44.07 (-1.34), BIOD: 0.34 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HI-CHEW® Holiday Mix Debuts Three Seasonal Flavors

HI-CHEW® Puts Holiday Cheer on the Shelves In the candy aisle, it’s never just about sugar—it’s about the flavor journey. This year, HI-CHEW® is pulling off a sweet, festive coup with its first-ever Holiday Mix, making sure that your taste buds aren't left out in the cold. But hey, I’m a seasoned investor talking about candy here, not stocks. Unwrapping the New...

Maternal Role in Type 1 Diabetes: A Non-Genetic Angle

Unveiling the Maternal Puzzle in Type 1 Diabetes So here's a stumper: how come kids of moms with type 1 diabetes dodge the disease more than kids of dads with it? Simple genes don't account for it, says a study from University of Colorado Anschutz. With nearly 7,000 kids in this research, you'd think they'd find a genetic smoking gun. Nope. It's pointing to something else...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

O-I Glass Faces Legal Storm Over Misleading Investor Claims

Turbulence Hits O-I Glass Stock Another day, another company in hot water—and today, it's O-I Glass, Inc. (NYSE: OI) we're talking about. The company's shares plummeted by 15.01% in one fell swoop on July 29, 2026, right after it dropped its financial bombshell. Let’s break this drama down, shall we? The Legal Brass Tacks Investors who took the bait on O-I Glass...

New CEO Aims to Revolutionize Pregnancy Health Sector

Revolution Brewing in Pregnancy Health Look, I’ve seen all sorts of execs take on new gigs, but when I hear about an industry veteran like David Stern stepping in as CEO at Mirvie, I sit up and take notice. It’s not just another leadership shuffle; it’s a potential game-changer for a slice of healthcare that’s long been due for an overhaul. Stern’s got a track...

Yiddish Prescription Labels Extend Language Access in NY

Here's something that might fly under the radar unless you're really in tune with how language impacts healthcare—RxTran's move to include Yiddish on prescription labels might not be rocking financial markets, but it's got a punchy little implication for those of us watching where healthcare intersects with real-world needs. A Push Toward Accessibility Healthcare...

AppLovin Faces Fraud Lawsuit, Investors Alerted

AppLovin's Lawsuit: A Wake-Up Call for Investors The market never forgets, even if some investors might wish reality wasn’t so harsh. On the chopping block this time is AppLovin Corporation (NASDAQ: APP). Seems like their fairy tale with AI turned into a courtroom drama, one that’s throwing a real curveball on those rosy earnings expectations. What's the Case All...

FFR Schedules Q3 2026 Earnings Call for November 12

FFR: On The Edge of Q3 2026 Results Ah, another quarter chock-full of intrigue over at FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR). With their third quarter financial results dropping on November 12, anxious investors are waiting to see some solid numbers amid the clouds of optimistic chatters. Nothing gets the heart racing for us seasoned stock folks like an upcoming...

Unveiling Federal Credit Lab: A Platform Revolution

Navigating the Maze of Federal Lending Well, folks, in the tangled web of federal economics, there's a new player aiming to bring some much-needed clarity. Lafayette Square Institute and the Center for USA Lending have rolled out the Federal Credit Lab. Think of it as a treasure trove of data and insights on federal credit, set to become a trusty compass for policymakers,...

Slim Chickens Redefines TV Dinners with Smart TV Orders

Slim Chickens Takes Over Your Living Room Folks, it looks like the couch just became a whole lot more than a place to binge-watch shows. Slim Chickens is shaking things up by letting you order your favorite wings and tenders right from the Samsung Smart TV home screen in Northwest Arkansas. This hell of a move takes fast-casual dining to a whole new level, mixing the...